Zentalis Pharmaceuticals, Inc. (ZNTL)
3.80
-0.08
(-2.06%)
USD |
NASDAQ |
Aug 28, 16:00
3.80
0.00 (0.00%)
After-Hours: 20:00
Zentalis Pharmaceuticals Shareholders Equity (Quarterly) : 143.65M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 143.65M |
| March 31, 2026 | 182.68M |
| December 31, 2025 | 216.20M |
| September 30, 2025 | 252.87M |
| June 30, 2025 | 274.50M |
| March 31, 2025 | 295.38M |
| December 31, 2024 | 337.19M |
| September 30, 2024 | 354.33M |
| June 30, 2024 | 382.58M |
| March 31, 2024 | 458.77M |
| December 31, 2023 | 437.28M |
| September 30, 2023 | 481.77M |
| June 30, 2023 | 523.14M |
| March 31, 2023 | 385.49M |
| Date | Value |
|---|---|
| December 31, 2022 | 433.80M |
| September 30, 2022 | 428.50M |
| June 30, 2022 | 472.49M |
| March 31, 2022 | 315.30M |
| December 31, 2021 | 363.95M |
| September 30, 2021 | 393.43M |
| June 30, 2021 | 223.84M |
| March 31, 2021 | 268.39M |
| December 31, 2020 | 308.58M |
| September 30, 2020 | 341.06M |
| June 30, 2020 | 213.22M |
| March 31, 2020 | -95.90M |
| December 31, 2019 | 61.60M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ARS Pharmaceuticals, Inc. | 12.51M |
| ACADIA Pharmaceuticals, Inc. | 1.307B |
| Alnylam Pharmaceuticals, Inc. | 1.354B |
| Anika Therapeutics, Inc. | 137.28M |
| Savara, Inc. | 143.66M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 215.33M |
| Total Liabilities (Quarterly) | 71.68M |
| Debt to Equity Ratio | 0.2624 |
| Current Ratio | 4.818 |
| Net Debt Paydown Yield | 0.06% |